Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

2000 • 1,536 citations

The anti-angiogenic basis of metronomic chemotherapy

2004 • 1,363 citations

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

2000 • 1,159 citations

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

2002 • 494 citations

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

2003 • 458 citations

Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer

1992 • 442 citations

Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.

2002 • 433 citations

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

2003 • 416 citations

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.

1996 • 349 citations

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

2002 • 313 citations

A Non-antibacterial Chemically-modified Tetracycline Inhibits Mammalian Collagenase Activity

1987 • 307 citations

Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer

2003 • 276 citations

Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine

1999 • 271 citations

Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors.

1994 • 270 citations

Metronomic scheduling: the future of chemotherapy?

2001 • 256 citations

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

2002 • 241 citations

Dose-response in the treatment of breast cancer: a critical review.

1988 • 227 citations

Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.

2001 • 182 citations

Using Cyclooxygenase-2 Inhibitors as Molecular Platforms to Develop a New Class of Apoptosis-Inducing Agents

2002 • 165 citations

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

2003 • 162 citations

Minimizing Long-Term Tumor Burden: The Logic for Metronomic Chemotherapeutic Dosing and its Antiangiogenic Basis

2003 • 140 citations

Rofecoxib (Vioxx) voluntarily withdrawn from market

2004 • 133 citations

Molecular Imaging of Antiangiogenic Agents

2005 • 132 citations

Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.

2003 • 128 citations

Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention

2004 • 121 citations

Antiangiogenic scheduling of lower dose cancer chemotherapy.

2001 • 120 citations

Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.

2002 • 120 citations

A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy

2003 • 118 citations

Therapeutic Potential of Selective Cyclooxygenase-2 Inhibitors in the Management of Tumor Angiogenesis

2003 • 116 citations

High-Time Chemotherapy or High Time for Low Dose

2000 • 107 citations

Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma

2004 • 95 citations

Inhibition of angiogenesis by non-toxic doses of temozolomide

2003 • 93 citations

Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma

1995 • 92 citations

Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.

1997 • 90 citations

Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.

2002 • 90 citations

A pilot study of use of the cyclooxygenase‐2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

2004 • 79 citations

Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy

1999 • 69 citations

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant.

1998 • 68 citations

Selective Cyclooxygenase-2 Inhibition: A Target in Cancer Prevention and Treatment

2003 • 59 citations

Reduced tumor oxygenation by treatment with vinblastine.

2001 • 38 citations

Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer

2006 • 30 citations

Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine

1999 • 30 citations

Inhibitory Effect of Minocycline on in Vitro Invasion and Experimental Metastasis of Mouse Renal Adenocarcinoma

1994 • 25 citations

Metronomic therapy for breast cancer

2004 • 22 citations

Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials

2000 • 22 citations

Prospective pilot study of the preoperative use of celecoxcib and FEC for the treatment of locally advanced breast cancer

2003 • 7 citations

Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide

2004 • 6 citations

Minocycline Inhibits In Vitro Invasion and Experimental Pulmonary Metastasis of Mouse Renal Adenocarcinoma

1998 • 5 citations

Phase I/II trial of a twice-daily regimen of temozolomide and celecoxib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma

2004 • 1 citations